Noema Pharma Appoints Volker Knappertz, M.D., as Executive Vice President of Research & Development [Yahoo! Finance]
Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
Last aurinia pharmaceuticals inc - common shares earnings: 3/5 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.auriniapharma.com
Company Research
Source: Yahoo! Finance
central nervous system (CNS) disorders, today announced the appointment of Volker Knappertz, M.D., as Executive Vice President of Research & Development. “We are excited to welcome Volker to Noema. Volker is a recognized leader in drug development with a proven track record building and leading Research and Development organizations and obtaining market approvals for novel drugs, including Epidiolex for the treatment of rare developmental childhood onset forms of epilepsy,” said Ilise Lombardo, M.D., Chief Executive Officer of Noema Pharma. “His experience and expertise across CNS development will be pivotal as Noema enters a transformational year with readouts of multiple Phase 2 studies across our pipeline.” “I am thrilled to join Noema and look forward to the continued clinical development across the company's multiple indications including seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms o
Show less
Read more
Impact Snapshot
Event Time:
AUPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUPH alerts
High impacting Aurinia Pharmaceuticals Inc - Common Shares news events
Weekly update
A roundup of the hottest topics
AUPH
News
- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options [Yahoo! Finance]Yahoo! Finance
- Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis [Yahoo! Finance]Yahoo! Finance
- Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus NephritisBusiness Wire
- Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024Business Wire
AUPH
Earnings
- 11/7/24 - Beat
AUPH
Sec Filings
- 12/9/24 - Form 4
- 11/25/24 - Form 4
- 11/25/24 - Form 4
- AUPH's page on the SEC website